Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode

Biochemical and Biophysical Research Communications

Volumn 363, Issue 3, 2007, Pages 554-560

  Barreca, Maria Letizia ^a   Ortuso, Francesco ^b   Iraci, Nunzio ^a   De Luca, Laura ^a   Alcaro, Stefano ^b   Chimirri, Alba ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Diketo acids (DKAs); HIV 1 integrase; Molecular dynamics; Tn5 transposase

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; INTEGRASE; INTEGRASE INHIBITOR; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; TRANSPOSASE;

ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; DRUG DESIGN; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DNA BINDING; SIMULATION; STRUCTURE ACTIVITY RELATION; VIRUS MUTATION;

BINDING SITES; COMPUTER SIMULATION; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPOSASES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34848914794     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.08.199     Document Type: Article

References (26)

1. Vandegraaff N., and Engelman A. Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev. Mol. Med. 9 (2007) 1-19
2. Pommier Y., Johnson A.A., and Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4 (2005) 236-248
3. Gordon C.P., Griffith R., and Keller P.A. Control of HIV through the inhibition of HIV-1 integrase: a medicinal chemistry perspective. Med. Chem. 3 (2007) 199-220
4. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., and Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287 (2000) 646-650
5. Zhuang L., Wai J.S., Embrey M.W., Fisher T.E., Egbertson M.S., Payne L.S., Guare Jr. J.P., Vacca J.P., Hazuda D.J., Felock P.J., Wolfe A.L., Stillmock K.A., Witmer M.V., Moyer G., Schleif W.A., Gabryelski L.J., Leonard Y.M., Lynch Jr. J.J., Michelson S.R., and Young S.D. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 46 (2003) 453-456
6. Marchand C., Johnson A.A., Karki R.G., Pais G.C., Zhang X., Cowansage K., Patel T.A., Nicklaus M.C., Burke Jr. T.R., and Pommier Y. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol. Pharmacol. 64 (2003) 600-609
7. Espeseth A.S., Felock P., Wolfe A., Witmer M., Grobler J., Anthony N., Egbertson M., Melamed J.Y., Young S., Hamill T., Cole J.L., and Hazuda D.J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl. Acad. Sci. USA 97 (2000) 11244-11249
8. Barreca M.L., De Luca L., Iraci N., and Chimirri A. Binding mode prediction of strand transfer HIV-1 integrase inhibitors using Tn5 transposase as a plausible surrogate model for HIV-1 integrase. J. Med. Chem. 49 (2006) 3994-3997
9. Ason B., Knauss D.J., Balke A.M., Merkel G., Skalka A.M., and Reznikoff W.S. Targeting Tn5 transposase identifies human immunodeficiency virus type 1 inhibitors. Antimicrob. Agents Chemother. 49 (2005) 2035-2043
10. Rice P.A., and Baker T.A. Comparative architecture of transposase and integrase complexes. Nat. Struct. Biol. 8 (2001) 302-307
11. Barreca M.L., Ferro S., Rao A., De Luca L., Zappala M., Monforte A.M., Debyser Z., Witvrouw M., and Chimirri A. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 48 (2005) 7084-7088
12. Oostenbrink C., Villa A., Mark A.E., and van Gunsteren W.F. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. Chem. 25 (2004) 1656-1676
13. Berendsen H.J.C., Van der Spoel D., and Van Drunen R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 91 (1995) 43-56
14. Berendsen H.J.C., Postma J.P.M., Van Gunsteren W.F., and Hermans J. Intermolecular Forces, Chapter Interaction Models for Water in Relation to Protein Hydration (1981), D. Reidel Publishing Company Dordrecht, Dordrecht pp. 331-342
15. Schuettelkopf A.W., and Van Aalten D.M.F. PRODRG - a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D60 (2004) 1355-1363
16. Jaguar v. 4.1, Schrödinger Inc., Portland, OR, 1998-2001.
17. Wallace A.C., Laskowski R.A., and Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Prot. Eng. 8 (1995) 127-134
18. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 4 (2003) 206-209
19. Marchand C., Zhang X., Pais G.C., Cowansage K., Neamati N., Burke Jr. T.R., and Pommier Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 277 (2002) 12596-12603
20. Savarino A. In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 4 (2007) 21
21. Hopkins C.R., O'Neil S V., Laufersweiler M.C., Wang Y., Pokross M., Mekel M., Evdokimov A., Walter R., Kontoyianni M., Petrey M.E., Sabatakos G., Roesgen J.T., Richardson E., and Demuth Jr. T.P. Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. Bioorg. Med. Chem. Lett. 16 (2006) 5659-5663
22. Discovery Studio 1.6; Accelrys Inc., San Diego, CA, USA.
23. Fikkert V., Hombrouck A., Van Remoortel B., De Maeyer M., Pannecouque C., De Clercq E., Debyser Z., and Witvrouw M. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18 (2004) 2019-2028
24. Hazuda D.J., Anthony N.J., Gomez R.P., Jolly S.M., Wai J.S., Zhuang L., Fisher T.E., Embrey M., Guare Jr. J.P., Egbertson M.S., Vacca J.P., Huff J.R., Felock P.J., Witmer M.V., Stillmock K.A., Danovich R., Grobler J., Miller M.D., Espeseth A.S., Jin L., Chen I.W., Lin J.H., Kassahun K., Ellis J.D., Wong B.K., Xu W., Pearson P.G., Schleif W.A., Cortese R., Emini E., Summa V., Holloway M.K., and Young S.D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 101 (2004) 11233-11238
25. G. Jones, R.M. Ledford, F. Yu, X. Chen, M.D. Miller, M. Tsiang, D.J. McColl, In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, 2007.
26. W.L. DeLano The PyMOL Molecular Graphics System. DeLano Scientific LLC, San Carlos, CA, USA. http://www.pymol.org.